Robert L Murphy

List of Publications by Citations

177 papers	8,424 citations	44 h-index	89 g-index
197 ext. papers	9,323 ext. citations	6.7 avg, IF	5.07 L-index

#	Paper	IF	Citations
177	Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. *New England Journal of Medicine*, **1990**, 322, 941-9	59.2	1113
176	Class-sparing regimens for initial treatment of HIV-1 infection. *New England Journal of Medicine*, **2008**, 358, 2095-106	59.2	575
175	Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. *New England Journal of Medicine*, **2004**, 350, 1850-61	59.2	429
174	Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *New England Journal of Medicine*, **2003**, 349, 2293-303	59.2	291
173	Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. *Journal of the American College of Cardiology*, **2008**, 52, 569-76	15.1	240
172	Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. *Aids*, **2009**, 23, 817-24	3.5	193
171	Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. *Aids*, **2001**, 15, 2407-14	3.5	180
170	Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. *PLoS Medicine*, **2004**, 1, e19	11.6	176
169	ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. *Aids*, **2001**, 15, F1-9	3.5	175
168	Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2006**, 296, 769-81	27.4	173
167	The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. *AIDS Research and Human Retroviruses*, **2002**, 18, 685-93	1.6	170
166	Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. *Journal of Pain and Symptom Management*, **1997**, 14, 7-14	4.8	162
165	Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. *Journal of Infectious Diseases*, **2002**, 185, 599-607	7	155
164	Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. *New England Journal of Medicine*, **1998**, 339, 1889-95	59.2	145
163	Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. *Journal of Virology*, **2003**, 77, 12336-45	6.6	141
162	Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. *Aids*, **2003**, 17, 2603-14	3.5	140
161	Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. *Journal of Infectious Diseases*, **2011**, 204, 1191-201	7	133

160	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. *Aids*, **2003**, 17, 987-99	3.5	131
159	Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2000**, 284, 183-9	27.4	130
158	Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. *American Journal of Ophthalmology*, **2002**, 133, 48-61	4.9	124
157	Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. *Clinical Infectious Diseases*, **2011**, 53, 1283-90	11.6	112
156	A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. *Aids*, **2003**, 17, 691-8	3.5	104
155	Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. *Journal of Infectious Diseases*, **2010**, 201, 1686-96	7	99
154	The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. *Aids*, **2012**, 26, 1231-41	3.5	95
153	Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. *Clinical Infectious Diseases*, **2009**, 49, 1268-73	11.6	92
152	Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. *Clinical Infectious Diseases*, **2015**, 61, 651-60	11.6	91
151	Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. *Aids*, **2004**, 18, 775-9	3.5	86
150	Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. *Journal of Infectious Diseases*, **2015**, 212, 1241-9	7	85
149	Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2004**, 36, 684-92	3.1	80
148	Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. *Ophthalmology*, **2005**, 112, 771-9	7.3	76
147	Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. *Journal of Infectious Diseases*, **1993**, 167, 1184-8	7	75
146	Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis. *PLoS ONE*, **2017**, 12, e0183924	3.7	72
145	Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). *Aids*, **2008**, 22, 1313-22	3.5	70
144	A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). *Aids*, **2000**, 14, 1601-10	3.5	65
143	A family history study of male sexual orientation using three independent samples. *Behavior Genetics*, **1999**, 29, 79-86	3.2	65

142	Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. *Journal of Infectious Diseases*, **2002**, 186, 1092-7	7	63
141	Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2010**, 54, 85-92	3.1	62
140	A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. *Aids*, **2015**, 29, 1775-83	3.5	59
139	Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2007**, 45, 304-10	3.1	58
138	Dolutegravir for the treatment of HIV. *Expert Opinion on Investigational Drugs*, **2012**, 21, 523-30	5.9	57
137	Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. *HIV Clinical Trials*, **2008**, 9, 1-10		51
136	Transient viremia in HIV-infected patients and use of plasma preparation tubes. *Clinical Infectious Diseases*, **2005**, 41, 1671-4	11.6	49
135	Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV*, **2011**, 23, 775-85	2.2	48
134	Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. *Clinical Infectious Diseases*, **1992**, 14, 183-8	11.6	47
133	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. *Aids*, **2016**, 30, 221-30	3.5	43
132	Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. *Aids*, **2013**, 27, 929-937	3.5	41
131	Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. *Journal of Antimicrobial Chemotherapy*, **2009**, 63, 1244-50	5.1	41
130	Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. *Aids*, **2010**, 24, 885-90	3.5	40
129	Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. *Journal of Infectious Diseases*, **2013**, 208, 512-9	7	39
128	The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). *Journal of Infectious Diseases*, **2002**, 186, 198-204	7	39
127	Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. *Aids*, **1999**, 13, 685-94	3.5	38
126	Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2013**, 63, 323-30	3.1	37
125	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. *Aids*, **2011**, 25, 27-36	3.5	37

124	Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. *PLoS ONE*, **2012**, 7, e30306	3.7	37
123	A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. *Journal of NeuroVirology*, **2011**, 17, 438-47	3.9	35
122	Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2009**, 51, 60-4	3.1	35
121	Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. *Future Virology*, **2011**, 6, 157-177	2.4	34
120	Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2009**, 52, 228-34	3.1	33
119	Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. *Clinical Infectious Diseases*, **2007**, 44, 749-54	11.6	32
118	Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. *HIV Clinical Trials*, **2007**, 8, 213-20		32
117	HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. *Aids*, **2002**, 16, 387-96	3.5	32
116	The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. *Aids*, **2000**, 14, 463-5	3.5	32
115	Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. *Clinical Infectious Diseases*, **2004**, 39, 1500-6	11.6	30
114	Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 2943-8	5.1	28
113	Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. *Lancet HIV,the*, **2015**, 2, e82-91	7.8	27
112	Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. *Journal of Clinical Lipidology*, **2008**, 2, 464-471	4.9	27
111	Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. *Journal of Acquired Immune Deficiency Syndromes*, **1999**, 22, 39-48		25
110	Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria. *Clinical Infectious Diseases*, **2013**, 57, e189-92	11.6	23
109	Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results. *Drugs*, **2010**, 70, 1629-42	12.1	21
108	Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients. *Aids*, **2008**, 22, 2212-4	3.5	21
107	Defining the toxicity profile of nevirapine and other antiretroviral drugs. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2003**, 34 Suppl 1, S15-20	3.1	21

106	A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l. *Aids*, **2001**, 15, 1509-15	3.5	21
105	HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. *PLoS ONE*, **2014**, 9, e85371	3.7	21
104	Aerosol pentamidine prophylaxis following pneumocystis carinii pneumonia in AIDS patients: Results of a blinded dose-comparison study using an ultrasonic nebulizer. *American Journal of Medicine*, **1991**, 90, 418-426	2.4	19
103	High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naive HIV-infected Children in Mali. *Pediatric Infectious Disease Journal*, **2017**, 36, e258-e263	3.4	18
102	Enhancement of health research capacity in Nigeria through north-south and in-country partnerships. *Academic Medicine*, **2014**, 89, S93-7	3.9	18
101	DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. *Clinical Epigenetics*, **2019**, 11, 145	7.7	17
100	Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a. *Journal of Infectious Diseases*, **2012**, 205, 1443-7	7	17
99	Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. *Aids*, **2000**, 14, 1553-61	3.5	17
98	Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. *American Journal of Ophthalmology*, **1994**, 117, 776-82	4.9	17
97	Cervical cancer survival in a resource-limited setting-North Central Nigeria. *Infectious Agents and Cancer*, **2016**, 11, 15	3.5	16
96	Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. *Advances in Therapy*, **2010**, 27, 1-16	4.1	16
95	Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. *Aids*, **2001**, 15, 591-9	3.5	16
94	Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. *Current HIV Research*, **2010**, 8, 194-8	1.3	16
93	Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study. *AIDS Research and Human Retroviruses*, **2013**, 29, 931-7	1.6	15
92	Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 2445-9	5.1	14
91	A SARS-CoV-2 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and Transmission to Inform Policy. *Journal of Medical Internet Research*, **2020**, 22, e24248	7.6	14
90	miRNA-Processing Gene Methylation and Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 550-557	4	13
89	Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 7852-6	5.9	13

88	Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1370-6	5.1	13
87	Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa. *Cytometry Part B - Clinical Cytometry*, **2008**, 74 Suppl 1, S11-8	3.4	13
86	Adherence to antiretroviral therapy in resource-limited settings: everything matters. *Aids*, **2007**, 21, 1041-3	3.5	13
85	Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection. *Antiviral Therapy*, **2005**, 10, 13-28	1.6	13
84	Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	12
83	High-risk human papillomavirus among HIV-infected women with normal cervical cytology: a pilot study in Jos, Nigeria. *Archives of Gynecology and Obstetrics*, **2013**, 288, 1365-70	2.5	12
82	Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Ségou and Bamako, Mali. *AIDS Research and Human Retroviruses*, **2013**, 29, 182-6	1.6	12
81	Chicago medical response to the 2010 earthquake in Haiti: translating academic collaboration into direct humanitarian response. *Disaster Medicine and Public Health Preparedness*, **2010**, 4, 169-73	2.8	12
80	Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis Study. *Journal of Medical Internet Research*, **2020**, 22, e24286	7.6	12
79	Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. *Journal of Medical Virology*, **2013**, 85, 8-15	19.7	11
78	Brief Report: HIV/HBV Coinfection is a Significant Risk Factor for Liver Fibrosis in Tanzanian HIV-Infected Adults. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2017**, 76, 298-302	3.1	11
77	Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. *AIDS Research and Treatment*, **2012**, 2012, 703604	2.3	11
76	Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals. *Antiviral Therapy*, **2010**, 15, 185-92	1.6	11
75	Increased cardiovascular risk in HIV infection: drugs, virus and immunity. *Aids*, **2008**, 22, 1625-7	3.5	11
74	Evaluating therapeutic vaccines in patients infected with HIV. *Expert Review of Vaccines*, **2004**, 3, S169-77	5.2	11
73	Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. *AIDS Research and Human Retroviruses*, **2005**, 21, 689-95	1.6	11
72	The AIDS autopsy spleen: a comparison of the pre-anti-retroviral and highly active anti-retroviral therapy eras. *Modern Pathology*, **2002**, 15, 406-12	9.8	11
71	Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. *Clinical Infectious Diseases*, **2016**, 62, 512-8	11.6	10

70	Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 65-79	4	10
69	Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2013**, 62, 204-7	3.1	10
68	Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. *Therapeutics and Clinical Risk Management*, **2009**, 5, 331-40	2.9	10
67	Management of antiretroviral failure and resistance in developing countries. *Current Opinion in HIV and AIDS*, **2009**, 4, 538-44	4.2	10
66	Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 820-828	5.1	10
65	Hepatitis B virus coinfection is associated with high early mortality in HIV-infected Tanzanians on antiretroviral therapy. *Aids*, **2019**, 33, 465-473	3.5	10
64	Dyslipidemia in ART-Naive HIV-Infected Persons in Nigeria--Implications for Care. *Journal of the International Association of Providers of AIDS Care*, **2015**, 14, 355-9	1.7	9
63	Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. *Journal of Antimicrobial Chemotherapy*, **1989**, 24, 591-604	5.1	9
62	Surveillance of the Second Wave of COVID-19 in Europe: Longitudinal Trend Analyses. *JMIR Public Health and Surveillance*, **2021**, 7, e25695	11.4	9
61	Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 1147-1151	5.1	9
60	Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. *Antiviral Therapy*, **2005**, 10, 13-28	1.6	9
59	A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 731-8	5.1	8
58	DNA Methylation of Telomere-Related Genes and Cancer Risk. *Cancer Prevention Research*, **2018**, 11, 511-522	3.2	8
57	Predictors of atypical squamous cell of undetermined significance cervical cytology with high-risk human papilloma virus genotypes. *Archives of Gynecology and Obstetrics*, **2011**, 283, 343-8	2.5	8
56	Presentation and survival in patients with hematologic malignancies in Jos, Nigeria: A retrospective cohort analysis. *Journal of Medicine in the Tropics*, **2018**, 20, 49-56	0.1	8
55	Perspectives for immunotherapy: which applications might achieve an HIV functional cure?. *Oncotarget*, **2016**, 7, 38946-38958	3.3	8
54	Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings. *Clinical Infectious Diseases*, **2019**, 68, 1733-1738	11.6	8
53	Promoter methylation of PGC1A and PGC1B predicts cancer incidence in a veteran cohort. *Epigenomics*, **2018**, 10, 733-743	4.4	7

52	High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology. *Infectious Agents and Cancer*, **2014**, 9, 36	3.5	7
51	Antiretroviral therapy for advanced naïve HIV-infected patients: current status and comparison of two different management strategies. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2007**, 46 Suppl 1, S1-2	3.1	7
50	HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. *PLoS ONE*, **2016**, 11, e0160341	3.7	7
49	SARS-CoV-2 Surveillance in the Middle East and North Africa: Longitudinal Trend Analysis. *Journal of Medical Internet Research*, **2021**, 23, e25830	7.6	7
48	Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings. *Journal of the International Association of Providers of AIDS Care*, **2013**, 12, 236-40	1.7	6
47	Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection. *Vaccine Journal*, **2001**, 8, 1277-8		6
46	Has Omicron Changed the Evolution of the Pandemic?. *JMIR Public Health and Surveillance*, **2022**,	11.4	6
45	SARS-CoV-2 Wave Two Surveillance in East Asia and the Pacific: Longitudinal Trend Analysis. *Journal of Medical Internet Research*, **2021**, 23, e25454	7.6	6
44	Hepatitis B virus sequencing and liver fibrosis evaluation in HIV/HBV co-infected Nigerians. *Tropical Medicine and International Health*, **2017**, 22, 744-754	2.3	5
43	Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG. *AIDS Research and Human Retroviruses*, **2008**, 24, 1167-74	1.6	5
42	Surveillance Metrics of SARS-CoV-2 Transmission in Central Asia: Longitudinal Trend Analysis. *Journal of Medical Internet Research*, **2021**, 23, e25799	7.6	5
41	Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria. *Infectious Agents and Cancer*, **2017**, 12, 34	3.5	4
40	A step ahead on the HIV collaboratory. *Science*, **2009**, 324, 1264-5	33.3	4
39	The marriage of science and optimized HIV care in resource-limited settings. *Aids*, **2008**, 22, 2227-30	3.5	4
38	Reviving Protease Inhibitors. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2003**, 33, S43???S52	3.1	4
37	Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. *Journal of Infectious Diseases*, **2002**, 186, 1013-8	7	4
36	HIV status, age at cervical Cancer screening and cervical cytology outcomes in an opportunistic screening setting in Nigeria: a 10-year Cross sectional data analysis. *Infectious Agents and Cancer*, **2019**, 14, 43	3.5	4
35	Reviving protease inhibitors: new data and more options. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2003**, 33 Suppl 1, S43-52; quiz S53, S55-6	3.1	4

34	Impact of the COVID-19 pandemic on global health research training and education. *Journal of Global Health*, **2020**, 10, 020366	4.3	3
33	Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). *Open Forum Infectious Diseases*, **2018**, 5, ofy103	1	3
32	Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2012**, 61, 293-6	3.1	3
31	Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2010**, 54, 563-5	3.1	3
30	Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis. *Aids*, **2002**, 16, 757-65	3.5	3
29	SARS-CoV-2 Surveillance System in Canada: Longitudinal Trend Analysis. *JMIR Public Health and Surveillance*, **2021**, 7, e25753	11.4	3
28	Evaluation of Two HIV Rapid Diagnostic Tests in a Context of StrainsPGenetic Diversity in Mali. *AIDS Research and Human Retroviruses*, **2019**, 35, 145-149	1.6	2
27	Corticosteroids, Cytotoxic Agents, and Infection605-610		2
26	Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings. *Journal of the International Association of Providers of AIDS Care*, **2007**, 6, 188-97		2
25	Latin America and the Caribbean SARS-CoV-2 Surveillance: Longitudinal Trend Analysis. *JMIR Public Health and Surveillance*, **2021**, 7, e25728	11.4	2
24	The Interplay Between Policy and COVID-19 Outbreaks in South Asia: Longitudinal Trend Analysis of Surveillance Data. *JMIR Public Health and Surveillance*, **2021**, 7, e24251	11.4	2
23	Association between patient-reported HIV status and provider recommendation for screening in an opportunistic cervical Cancer screening setting in Jos, Nigeria. *BMC Health Services Research*, **2018**, 18, 885	2.9	2
22	Comparison of Rapid Antigen TestsPPerformance between Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study. **2022**,		2
21	Changes in liver stiffness after ART initiation in HIV-infected Nigerian adults with and without chronic HBV. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 2003-2008	5.1	1
20	Reply to Phillips. *Clinical Infectious Diseases*, **2005**, 40, 1380-1381	11.6	1
19	Lopinavir. *Drugs*, **2000**, 60, 1380-1381	12.1	1
18	SARS-CoV-2 Surveillance System in Canada: Longitudinal Trend Analysis (Preprint)		1
17	Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).. *Open Forum Infectious Diseases*, **2021**, 8, ofab511	1	1

List of Publications

16	A preprogram appraisal of factors influencing research productivity among faculty at college of medicine, University of Lagos. *Annals of African Medicine*, **2020**, 19, 124-130	1.7	1
15	HIV and development of epithelial cell abnormalities in women with prior normal cervical cytology in Nigeria. *Infectious Agents and Cancer*, **2020**, 15, 50	3.5	1
14	p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies. *BMC Medical Genetics*, **2020**, 21, 206	2.1	1
13	Excess early mortality in HIV/hepatitis B virus co-infected patients initiating antiretroviral therapy in Kenya. *Aids*, **2019**, 33, 1404-1406	3.5	1
12	Effect of Baseline Symptom Manifestations on Retention in Care and Treatment among HIV-Infected Patients in Nigeria. *Journal of the International Association of Providers of AIDS Care*, **2020**, 19, 2325958220903575	1.7	0
11	Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1272-1279	5.1	0
10	C-THAN: A new research center for the development of point-of-care technology for HIV/AIDS **2019**, 2, 1-5		0
9	From Creation to Evaluation: A Comprehensive Global Health Scholars Program for Graduate Medical Education Trainees. *Journal of Medical Education and Curricular Development*, **2020**, 7, 2382120520951821	2.2	0
8	Corticosteroids, cytotoxic agents, and infection563-566		
7	Introduction. *Clinical Infectious Diseases*, **2000**, 30 Suppl 2, S95	11.6	
6	The problem of resistance in may be underestimated in Africa. *International Journal of Mycobacteriology*, **2018**, 7, 148-151	0.9	
5	Immunovirological and Biochemical Changes in Nigerian Patients with Hepatitis B Coinfection on Antiretroviral Therapy. *World Journal of AIDS*, **2011**, 01, 31-36	0.3	
4	Short Communication: Genetic Variation in Human Proximal Promoter and Susceptibility to HIV-1 Infection in Mali, West Africa. *AIDS Research and Human Retroviruses*, **2021**, 37, 57-61	1.6	
3	Utilizing a new class of antiretrovirals: role of fusion inhibitors in HIV disease management. *Aids Reader*, **2003**, 13, S12-8		
2	Analyses of Kaposi Sarcoma trends among adults establishing initial outpatient HIV care in Nigeria: 2006-2017.. *Infectious Agents and Cancer*, **2022**, 17, 10	3.5	
1	Accelerated Epigenetic Age Among Women with Invasive Cervical Cancer and HIV-Infection in Nigeria.. *Frontiers in Public Health*, **2022**, 10, 834800	6	